Patient Engagement Drives NSCLC Testing – Julia Rotow, MD
- An interview with Julia Rotow, MD, on the challenges and advancements in biomarker testing for NSCLC, particularly within community practices.
- Julia Rotow, MD, of the Dana-Farber Cancer Institute, discussed the continually evolving definition of comprehensive testing in non-small cell lung cancer (NSCLC) in a recent interview with the...
- Rotow's insights stem from her moderation of the panel, "Value-Driven Precision: Advancing Equitable access to Targeted and Immuno-Oncology Therapies in Lung cancer," at the Institute for Value-Based Medicine...
“`html
Evolving Comprehensive Testing in Non-Small Cell Lung Cancer
Table of Contents
An interview with Julia Rotow, MD, on the challenges and advancements in biomarker testing for NSCLC, particularly within community practices.
The Evolving Landscape of NSCLC Testing
Julia Rotow, MD, of the Dana-Farber Cancer Institute, discussed the continually evolving definition of comprehensive testing in non-small cell lung cancer (NSCLC) in a recent interview with the american Journal of Managed Care®. This evolution is driven by the emergence of new biomarkers and therapies, creating complexities, especially for community-based practices. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80-85% of all cases.
Dr. Rotow’s insights stem from her moderation of the panel, “Value-Driven Precision: Advancing Equitable access to Targeted and Immuno-Oncology Therapies in Lung cancer,” at the Institute for Value-Based Medicine regional event held in Boston. The Boston event focused on driving the future of cancer care.
challenges in Precision Medicine Uptake
A prior segment of the interview,part 1, highlighted the variability in the adoption of precision medicine approaches for NSCLC. dr. Rotow emphasized the critical importance of biomarker testing in this patient population. This variability is frequently enough linked to factors like access to specialized testing, physician familiarity with emerging biomarkers, and health system fragmentation.
Health system fragmentation, as Dr. Rotow points out, substantially undermines timely lung cancer testing. This fragmentation can lead to delays in diagnosis and treatment, ultimately impacting patient outcomes.
The Role of biomarker Testing
Biomarker testing is crucial for identifying specific genetic mutations or protein expressions within a tumor. These biomarkers can predict a patient’s response to targeted therapies and immunotherapies. Common biomarkers tested in NSCLC include:
- EGFR: Epidermal Growth Factor Receptor
- ALK: Anaplastic Lymphoma Kinase
- ROS1: ROS Proto-Oncogene 1
- BRAF: B-Raf Proto-Oncogene
- PD-L1: Programmed Death-Ligand 1
The National Comprehensive Cancer Network (NCCN) provides detailed guidelines for biomarker testing in NSCLC.